Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 9/20 | 0.48 |
| ▸ | CNR2 | P34972 | 9/20 | 0.48 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.46 |
| ▸ | KLK1 | P06870 | 2/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5761223 | 0.90 | ELANE (0.55) | ELANECNR1CNR2KLKB1KLK1 | |
| SCHEMBL5757342 | 0.90 | ELANE (0.50) | ELANEKLKB1KLK1APEX1NOTUM | |
| SCHEMBL5756911 | 0.88 | ELANE (0.57) | ELANEKLKB1KLK1NOTUMMEN1 | |
| SCHEMBL5756141 | 0.87 | ELANE (0.52) | ELANEKLKB1KLK1NOTUMALDH1A1 | |
| SCHEMBL5757705 | 0.87 | ELANE (0.55) | ELANECNR1CNR2KLKB1KLK1 | |
| SCHEMBL5756777 | 0.87 | ELANE (0.54) | ELANEKLKB1KLK1NOTUMMETAP2 | |
| SCHEMBL5755823 | 0.87 | ELANE (0.58) | ELANEKLKB1KLK1NOTUMMEN1 | |
| SCHEMBL5756660 | 0.87 | ELANE (0.55) | ELANEKLKB1KLK1NOTUMKMT2A | |
| SCHEMBL5756216 | 0.86 | ELANE (0.51) | ELANEKLKB1KLK1APEX1NOTUM | |
| SCHEMBL5756946 | 0.86 | ELANE (0.50) | ELANEKLKB1KLK1NOTUMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562902-B1 | 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2006-05-03 | — | — | EP | disclosed |
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | ASRAZENECA AB (SE) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | SERPINB1, ELANE, SERPINE1 | ELANE 2/4885CNR1 2232/4885CNR2 2164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.